A Century After Umami#s Discovery, Its Benefits Continue to Expand

Food and Healthcare Press Releases Wednesday July 4, 2018 08:33
TOKYO--4 Jul--PRNewswire/InfoQuest
Latest Umami Research Confirms Appetite Control and Sodium Reduction Benefits

Umami, known as the savory taste, was discovered more than a century ago, yet recent research continues to document the benefits of umami. Currently underway is a year-long recognition of umami's 110th anniversary since its discovery in 1908.

At one event this year, participants at the Asian Congress of Dietetics (ACD) will discuss the latest research on umami, including its dietary significance, during an ACD lunch symposium on Friday, July 6. The symposium ties in directly to the theme of the 7th ACD, which is "The Rise of Nutrition and Dietetics in Asia," being held July 6-8 at the Hong Kong Polytechnic University.

The principal speaker at the lunch symposium will be Dr. Snigdha Misra, who is chair of the Department of Nutrition and Dietetics at International Medical University, in Malaysia. Dr. Snigdha will present the latest research demonstrating that umami improves the palatability of foods and stimulates appetite regulation, supporting nutrition among the elderly. Dr. Snigdha also will discuss how foods with umami seasonings are effective in reducing sodium intake and can help maintain normal blood pressure.

Dr. Snigdha notes, "The elderly face challenges in appetite due to decline in taste sensitivity. The addition of excessive sauces or dressings may make food appetizing, but could be detrimental to health due to the high sodium content. Umami enables food to be flavorful while lowering the sodium content of the food and stimulating appetite."

According to the International Glutamate Information Service (IGIS), sponsor of the symposium, "It is fitting that ACD is focusing on the rise of nutrition in Asia. It was in Japan that   110 years ago Professor Kikunae Ikeda identified the 'glutamic taste' after isolating it from kelp broth. Dr. Ikeda was the first scientist to identify the unique properties of glutamate. He named the taste of glutamate 'umami,' which has a distinctive taste that is different from sweet, sour, bitter, and salty. Umami is now recognized as one of the five basic tastes. Dr. Ikeda's driving goal was to improve nutrition of the Japanese with his umami seasoning."

The IGIS is a non-profit organization communicating science-based information about umami, glutamate, and monosodium glutamate (umami seasoning). For more information, visit glutamate.org.

Latest Press Release

Beijing Intellectual Property Court Confirms Judgment Against Wuxi Hisky Medical for Patent Infringement of Technology Used for Echosens# FibroScan(R), Imposes Damages Orders Halt to Manufacturing and Sales

Echosens, an innovative high-technology company offering the FibroScan family of products dedicated to assessment of chronic liver disease, today announces that the Beijing Intellectual Property Court has confirmed judgment against Wuxi Hisky Medical,...

5 Ways to Set Healthy Grocery Shopping Habits in 2019

By Susan Bowerman, M.S., RD, CSSD, CSOWM, FAN, Senior Director, Worldwide Nutrition Education and Training Make your daily staples as healthy as you can. Small changes in the foods you eat every day can add up to big rewards. The holidays are over, and...

Texas Cardiac Arrhythmia Institute at St. David#s Medical Center first in U.S. to treat patient in study to evaluate balloon ablation catheter for treating Atrial Fibrillation

The Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center recently performed the first procedure in the U.S. using the new HELIOSTAR Multi-electrode Radiofrequency (RF) Balloon Ablation Catheter as part of the STELLAR study. The study...

FDA Accepts sBLA and Grants Priority Review for BAVENCIO(R) (avelumab) Plus INLYTA(R) (axitinib) for the Treatment of Advanced Renal Cell Carcinoma

Merck and Pfizer Inc. (NYSE: PFE) today announced that the US Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for BAVENCIO(R) (avelumab) in combination with INLYTA(R) (axitinib)*...

BioLineRx Announces Closing of $15.4 Million Underwritten Public Offering of its American Depositary Shares and Warrants

BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today announced that it has closed its previously announced underwritten public offering of 28,000,000 American Depositary Shares ("ADSs"),...

Related Topics